Business Wire

Carta to Acquire Sirvatus to Bring Tech-Enabled Loan Operations to Private Credit Fund CFOs

9.10.2025 16:00:00 EEST | Business Wire | Press release

Share

Carta, the software platform purpose-built for private capital, today announced that it has acquired Sirvatus, a leading loan administration platform for private credit funds. The acquisition makes Carta the first truly integrated platform for private credit fund CFOs, seamlessly combining fund administration, loan operations, and investor reporting into one end-to-end platform.

As investors pour capital into private credit — with assets under management surging to more than $1.7 trillion in 2024 and expected to reach $2.8 trillion by 2028* – private credit fund managers need next-generation tools to meet rising market demands for speed, accuracy, and transparency. Carta’s end-to-end Loan Operations solution replaces cumbersome, error-prone manual tasks—allowing managers to spend more time focused on investing and less on administration.

“With Sirvatus and Carta Loan Operations, we’re expanding Carta’s ERP for Private Capital to serve one of the industry's fastest growing asset classes in private credit,” said Henry Ward, Chief Executive Officer, Carta. “In the same way that we’ve helped venture and private equity CFOs automate their fund operations by connecting portfolio company cap table events with our fund accounting suite, Loan Operations allows private credit managers to effectively manage underlying loan data and integrate it into their fund workflows.”

With the acquisition of Sirvatus, Carta will offer:

  • Native support for complex structures: Capture bespoke deal terms like cash sweeps, PIK toggles, unitranche loans, and amendments directly from loan agreements in a purpose-built system.
  • Automated loan tracking: Real-time dashboards display current loan positions, payment schedules, interest rates, loan and portfolio-level returns modeling and compliance status.
  • Integrated accounting and reconciliation: Fund accounting updates instantly with every loan transaction, eliminating manual data entry and reconciliation.
  • Seamless investor reporting: Institutional investors received transparent, timely performance data and customizable reports through Carta’s consolidated LP Portal.
  • Scalable, audit-ready infrastructure: Built to support funds of all sizes, with automated workflows to ensure accuracy and streamline audits.

“Together with Carta, we unlock what private credit fund managers have long been missing: an interoperable solution connecting underlying asset data with their most critical fund workflows and reporting," said Trevor Cook, Chief Executive Officer, Sirvatus. “Our shared vision is to give every private credit fund, regardless of size, access to purpose-built technology and real-time data to transform how they operate. We look forward to continuing to execute on this vision alongside the Carta team.”

The acquisition of Sirvatus follows a period of significant growth and strategic expansion for Carta. Last week, Carta announced the acquisition of Accelex, enhancing its ability to automate and streamline data extraction and analysis for private markets. Carta has also deepened its collaboration with some of the world's largest financial institutions, including an expanded partnership with Morgan Stanley Wealth Management to increase access and transparency for private market investments, and New York Stock Exchange, Carta’s preferred listing partner.

With these advancements, Carta is doubling down on its commitment to modernize private markets, equipping fund managers and investors with the tools they need to drive efficiency, transparency and growth. To stay connected, follow Carta on LinkedIn, X, Instagram, Youtube, or visit carta.com.

*Preqin Future of Alternatives 2028

About Carta

Carta connects founders, investors, and limited partners through world-class software purpose-built for everyone in venture capital and private equity. Carta's world-class fund administration platform supports 9,000+ funds and SPVs representing over $185B in assets under administration on fund administration, SPV formation, and more. Trusted by more than 65,000 companies, Carta helps private businesses in over 160 countries manage their cap tables, valuations, taxes, equity programs, compensation, and more. Carta has been included on the Fortune Best Large Workplaces in Financial Services and Insurance list, Forbes' list of the World's Best Cloud Companies, Fast Company's Most Innovative list, and Inc. 's Fastest-Growing Private Companies list. For more information, visit carta.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251009033334/en/

Contacts

Media Contact:
Carta
Amanda Taggart, VP Communications
press@carta.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye